Discovery of structure-based small molecular inhibitor of αb-crystallin against basal-like/triple-negative breast cancer development in vitro and in vivo

Breast Cancer Research and Treatment

Volumn 145, Issue 1, 2014, Pages 45-59

  Chen, Zhijuan ^a   Ruan, Qing ^a   Han, Song ^b   Xi, Lei ^c   Jiang, Wenguo ^d   Jiang, Huabei ^c   Ostrov, David A ^b   Cai, Jun ^a,d  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c J Crayton Pruitt Family Department of Biomedical Engineering   (United States)

^d CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

CRYAB; Small molecular inhibitor; TNBC

Indexed keywords

ALPHA CRYSTALLIN; ALPHAB CRYSTALLIN; ANTINEOPLASTIC AGENT; NCI 41356; UNCLASSIFIED DRUG; VASCULOTROPIN 165; 3-METHYLGLUTAMIC ACID; CRYAB PROTEIN, HUMAN; GLUTAMIC ACID; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; METASTASIS INHIBITION; MOLECULAR DOCKING; MOLECULARLY TARGETED THERAPY; NONHUMAN; PHOTOACOUSTICS; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; TRIPLE NEGATIVE BREAST CANCER; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG DEVELOPMENT; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; METABOLISM; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PROTEIN QUATERNARY STRUCTURE; TUMOR CELL LINE;

ALPHA-CRYSTALLIN B CHAIN; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG DISCOVERY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUTAMIC ACID; HUMANS; MICE; MICE, NUDE; MOLECULAR DOCKING SIMULATION; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN STRUCTURE, QUATERNARY; TRIPLE NEGATIVE BREAST NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84900489402     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-2940-8     Document Type: Article

References (42)

1. Braden MA, Stankowski VR, Engel MJ, Onitilo AA (2013) Breast cancer biomarkers: risk assessment, diagnosis, prognosis, prediction of treatment efficacy and toxicity, and recurrence. Curr Pharm Des
2. Reis-Filho JS, Tutt AN (2008) Triple negative tumours: a critical review. Histopathology 52(1):108-118. doi: 10.1111/j.1365-2559.2007.02889.x
3. Tischkowitz M, Brunet JS, Begin LR, Huntsman DG, Cheang MC, Akslen LA, Nielsen TO, Foulkes WD (2007) Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer 7:134. doi: 10.1186/1471-2407-7-134
4. Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, Lanchbury JS, Stemke-Hale K, Hennessy BT, Arun BK, Hortobagyi GN, Do KA, Mills GB, Meric-Bernstam F (2011) Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 17(5):1082-1089. doi: 10.1158/1078-0432.CCR-10-2560
5. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295(21):2492-2502. doi: 10.1001/jama.295.21.2492
6. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer 109(9):1721-1728. doi: 10.1002/cncr.22618
7. Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Dressler LG, Smith LV, Labbok MH, Geradts J, Bensen JT, Jackson S, Nyante S, Livasy C, Carey L, Earp HS, Perou CM (2008) Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 109(1):123-139. doi: 10.1007/s10549-007-9632-6
8. Kaplan HG, Malmgren JA, Atwood M (2009) T1N0 triple negative breast cancer: risk of recurrence and adjuvant chemotherapy. Breast J 15(5):454-460. doi: 10.1111/j.1524-4741.2009.00789.x
9. Huo D, Ikpatt F, Khramtsov A, Dangou JM, Nanda R, Dignam J, Zhang B, Grushko T, Zhang C, Oluwasola O, Malaka D, Malami S, Odetunde A, Adeoye AO, Iyare F, Falusi A, Perou CM, Olopade OI (2009) Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol 27(27):4515-4521. doi: 10.1200/JCO.2008.19.6873
10. Gravekamp C, Sypniewska R, Gauntt S, Tarango M, Price P, Reddick R (2004) Behavior of metastatic and nonmetastatic breast tumors in old mice. Exp Biol Med (Maywood) 229(7):665-675
11. Price DJ, Avraham S, Jiang S, Fu Y, Avraham HK (2004) Role of the aging vasculature and Erb B-2 signaling in epidermal growth factor-dependent intravasion of breast carcinoma cells. Cancer 101(1):198-205. doi: 10.1002/cncr.20340
12. Xiong W, Li J, Chen L, Price RA, Freedman G, Ding M, Qin L, Yang J, Ma CM (2004) Optimization of combined electron and photon beams for breast cancer. Phys Med Biol 49(10):1973-1989
13. Kim LS, Huang S, Lu W, Lev DC, Price JE (2004) Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice. Clin Exp Metastasis 21(2):107-118
14. Lee S, Chen TT, Barber CL, Jordan MC, Murdock J, Desai S, Ferrara N, Nagy A, Roos KP, Iruela-Arispe ML (2007) Autocrine VEGF signaling is required for vascular homeostasis. Cell 130(4):691-703. doi: 10.1016/j.cell.2007.06.054
15. Samuel S, Fan F, Dang LH, Xia L, Gaur P, Ellis LM (2011) Intracrine vascular endothelial growth factor signaling in survival and chemoresistance of human colorectal cancer cells. Oncogene 30(10):1205-1212. doi: 10.1038/onc.2010.496onc2010496
16. Moyano JV, Evans JR, Chen F, Lu M, Werner ME, Yehiely F, Diaz LK, Turbin D, Karaca G, Wiley E, Nielsen TO, Perou CM, Cryns VL (2006) AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J Clin Invest 116(1):261-270. doi: 10.1172/JCI25888
17. Sitterding SM, Wiseman WR, Schiller CL, Luan C, Chen F, Moyano JV, Watkin WG, Wiley EL, Cryns VL, Diaz LK (2008) AlphaB-crystallin: a novel marker of invasive basal-like and metaplastic breast carcinomas. Ann Diagn Pathol 12(1):33-40. doi: 10.1016/j.anndiagpath.2007.02.004
18. Piatigorsky J (1984) Lens crystallins and their gene families. Cell 38(3):620-621
19. Iwaki T, Kume-Iwaki A, Goldman JE (1990) Cellular distribution of alpha B-crystallin in non-lenticular tissues. J Histochem Cytochem 38(1):31-39
20. Ruan Q, Han S, Jiang WG, Boulton ME, Chen ZJ, Law BK, Cai J (2011) alphaB-crystallin, an effector of unfolded protein response, confers anti-VEGF resistance to breast cancer via maintenance of intracrine VEGF in endothelial cells. Mol Cancer Res 9(12):1632-1643. doi: 10.1158/1541-7786.MCR-11-0327
21. Acunzo J, Katsogiannou M, Rocchi P (2012) Small heat shock proteins HSP27 (HspB1), alphaB-crystallin (HspB5) and HSP22 (HspB8) as regulators of cell death. Int J Biochem Cell Biol 44(10):1622-1631. doi: 10.1016/j.biocel.2012.04. 002
22. Lee JS, Kim HY, Jeong NY, Lee SY, Yoon YG, Choi YH, Yan C, Chu IS, Koh H, Park HT, Yoo YH (2012) Expression of alphaB-crystallin overrides the anti-apoptotic activity of XIAP. Neuro Oncol 14(11):1332-1345. doi: 10.1093/neuonc/nos247
23. Taylor RP, Benjamin IJ (2005) Small heat shock proteins: a new classification scheme in mammals. J Mol Cell Cardiol 38(3):433-444. doi: 10.1016/j.yjmcc.2004.12.014
24. Ousman SS, Tomooka BH, van Noort JM, Wawrousek EF, O'Connor KC, Hafler DA, Sobel RA, Robinson WH, Steinman L (2007) Protective and therapeutic role for alphaB-crystallin in autoimmune demyelination. Nature 448(7152):474-479. doi: 10.1038/nature05935
25. Ghosh JG, Shenoy AK Jr, Clark JI (2007) Interactions between important regulatory proteins and human alphaB crystallin. Biochemistry 46(21):6308-6317. doi: 10.1021/bi700149h
26. Cai J, Jiang WG, Grant MB, Boulton M (2006) Pigment epithelium-derived factor inhibits angiogenesis via regulated intracellular proteolysis of vascular endothelial growth factor receptor 1. J Biol Chem 281(6):3604-3613. doi: 10.1074/jbc.M507401200
27. Ruan Q, Xi L, Boye SL, Han S, Chen ZJ, Hauswirth WW, Lewin AS, Boulton ME, Law BK, Jiang WG, Jiang H, Cai J (2013) Development of an anti-angiogenic therapeutic model combining scAAV2-delivered siRNAs and noninvasive photoacoustic imaging of tumor vasculature development. Cancer Lett 332(1):120-129. doi: 10.1016/j.canlet.2012.11.016
28. Yang JM, Maslov K, Yang HC, Zhou Q, Shung KK, Wang LV (2009) Photoacoustic endoscopy. Opt Lett 34(10):1591-1593
29. Bagneris C, Bateman OA, Naylor CE, Cronin N, Boelens WC, Keep NH, Slingsby C (2009) Crystal structures of alpha-crystallin domain dimers of alphaB-crystallin and Hsp20. J Mol Biol 392(5):1242-1252. doi: 10.1016/j.jmb.2009.07.069
30. Derossi D, Joliot AH, Chassaing G, Prochiantz A (1994) The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem 269(14):10444-10450
31. Jehle S, Rajagopal P, Bardiaux B, Markovic S, Kuhne R, Stout JR, Higman VA, Klevit RE, van Rossum BJ, Oschkinat H (2010) Solid-state NMR and SAXS studies provide a structural basis for the activation of alphaB-crystallin oligomers. Nat Struct Mol Biol 17(9):1037-1042. doi: 10.1038/nsmb.1891
32. Chelouche-Lev D, Kluger HM, Berger AJ, Rimm DL, Price JE (2004) alphaB-crystallin as a marker of lymph node involvement in breast carcinoma. Cancer 100(12):2543-2548. doi: 10.1002/cncr.20304
33. Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8(8):592-603. doi: 10.1038/nrc2442
34. Kamradt MC, Lu M, Werner ME, Kwan T, Chen F, Strohecker A, Oshita S, Wilkinson JC, Yu C, Oliver PG, Duckett CS, Buchsbaum DJ, LoBuglio AF, Jordan VC, Cryns VL (2005) The small heat shock protein alpha B-crystallin is a novel inhibitor of TRAIL-induced apoptosis that suppresses the activation of caspase-3. J Biol Chem 280(12):11059-11066. doi: 10.1074/jbc.M413382200
35. van de Schootbrugge C, Bussink J, Span PN, Sweep FC, Grenman R, Stegeman H, Pruijn GJ, Kaanders JH, Boelens WC (2013) alphaB-crystallin stimulates VEGF secretion and tumor cell migration and correlates with enhanced distant metastasis in head and neck squamous cell carcinoma. BMC Cancer 13:128. doi: 10.1186/1471-2407-13-128
36. Duffy AM, Bouchier-Hayes DJ, Harmey JH (2000) Vascular endothelial growth factor (VEGF) and its role in non-endothelial cells: autocrine signalling by VEGF. Landes Bioscience. http://www.ncbi.nlm.nih.gov/books/NBK6482/
37. Masood R, Cai J, Zheng T, Smith DL, Hinton DR, Gill PS (2001) Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood 98(6):1904-1913
38. Mercurio AM, Lipscomb EA, Bachelder RE (2005) Non-angiogenic functions of VEGF in breast cancer. J Mammary Gland Biol Neoplasia 10(4):283-290. doi: 10.1007/s10911-006-9001-9
39. Kerr BA, Byzova TV (2011) alphaB-crystallin: a novel VEGF chaperone. Blood 115(16):3181-3183. doi: 10.1182/blood-2010-01-262766
40. Morrison LE, Whittaker RJ, Klepper RE, Wawrousek EF, Glembotski CC (2004) Roles for alphaB-crystallin and HSPB2 in protecting the myocardium from ischemia-reperfusion-induced damage in a KO mouse model. Am J Physiol Heart Circ Physiol 286(3):H847-H855. doi: 10.1152/ajpheart.00715.2003
41. White AW, Westwell AD, Brahemi G (2008) Protein-protein interactions as targets for small-molecule therapeutics in cancer. Expert Rev Mol Med 10:e8. doi: 10.1017/S1462399408000641
42. Moreira IS, Fernandes PA, Ramos MJ (2007) Hot spots - a review of the protein-protein interface determinant amino-acid residues. Proteins 68(4):803-812. doi: 10.1002/prot.21396